137361-05-8
137361-05-8
Chemical Structure
Nω-Propyl-L-arginine
Synonym(s): N-omega-Propyl-L-arginine
- CAS No.: 137361-05-8
- Formula:C9H20N4O2
- Molecular Weight:216.28
IUPAC Name: Nw-propyl-L-arginine
InChIKey: AOMXURITGZJPKB-ZETCQYMHSA-N
SMILES: N=C(NCCC)NCCC[C@H](N)C(O)=O
Biological Activity: Nω-Propyl-L-arginine (N-omega-Propyl-L-arginine) is a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase (nNOS), with a Ki of 57 nM. Nω-Propyl-L-arginine displays a 149-fold selectivity for nNOS over endothelial NOS (eNOS)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nω-Propyl-L-arginine | 98.31% | Nω-Propyl-L-arginine (N-omega-Propyl-L-arginine) is a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase (nNOS), with a Ki of 57 nM. Nω-Propyl-L-arginine displays a 149-fold selectivity for nNOS over endothelial NOS (eNOS). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nω-Propyl-L-arginine (Standard) | ≥98% | Nω-Propyl-L-arginine (Standard) is the analytical standard of Nω-Propyl-L-arginine (HY-102062). This product is intended for research and analytical applications. Nω-Propyl-L-arginine (N-omega-Propyl-L-arginine) is a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase (nNOS), with a Ki of 57 nM. Nω-Propyl-L-arginine displays a 149-fold selectivity for nNOS over endothelial NOS (eNOS). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhang HQ, et al. Potent and selective inhibition of neuronal nitric oxide synthase by N omega-propyl-L-arginine. J Med Chem. 1997 Nov 21;40(24):3869-70. [Content Brief]
- [2]. Klamer D, et al. The neuronal selective nitric oxide synthase inhibitor, Nomega-propyl-L-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice. Eur J Pharmacol. 2004 Oct 25;503(1-3):103-7. [Content Brief]
